Study reveals mechanisms behind common mutation and prostate cancer

Researchers discovered two distinct ways mutation of the FOXA1 gene alters tumor formation and therapy resistance in prostate cancer in mouse models

2:00 PM

Author | Anna Megdell

two foxes on grass
Getty Images

A study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.

FOXA1, a key transcription factor that facilitates androgen receptor binding to DNA, is mutated in 10–40% of hormone-dependent prostate cancers.

While common, the exact ways these mutations alter cancer cells have remained elusive—until now.

Rogel researchers, including Arul Chinnaiyan, M.D., Ph.D., S.P. Hicks Endowed Professor of pathology and Urology, and Abhijit Parolia, Ph.D., Rogel Fellow and assistant professor of pathology, used mouse models to understand the mechanisms underlying two major classes of FOXA1 mutations.

In addition to establishing FOXA1 as a true oncogenic driver in prostate cancer, their findings reveal the distinct ways that each class of FOXA1 mutations operate.

Firstly, Class 1 mutations, commonly observed in primary prostate cancer, work with loss of the gene TP53 to promote the formation of aggressive tumors.

Like human prostate cancer, tumors in the mouse models retain hormone sensitivity and shrink in response to androgen deprivation therapy.

Alternatively, Class 2 mutations, typically found in metastatic prostate cancer, do not independently initiate tumor growth.

Instead, they reprogram the cellular lineage identity, driving resistance to hormonal therapies.

“This is the first in vivo demonstration of FOXA1 as an initiator of prostate cancer,” said Chinnaiyan. “Prior studies relied on cell lines, but our mouse models provide definitive evidence of its causal role in tumor development.”

These insights build on earlier work that categorized three major FOXA1 mutation types.

“This study goes further,” Chinnaiyan added, “by revealing how distinct alterations within the same gene can initiate disease in early stages or confer resistance in late-stage, therapy-refractory tumors.”

Hormone therapy is central to prostate cancer treatment.

Though initially effective, most patients develop resistance to androgen deprivation therapy, leading to incurable disease. 

“Modeling primary prostate cancer’s response to androgen withdrawal in mouse models has been challenging,” said Parolia.

“We demonstrated that prostate tumors driven by Class 1 mutations require continuous androgen supply for growth and survival, establishing the FOXA1/p53 mouse model as a valuable preclinical system.”

In metastatic disease, Class 2 mutants acquire the ability to access latent DNA sites.

“Activation of these sites turn on genes that drive adaptation to androgen blockade, enabling cancer’s escape from therapy,” Parolia explained.

The team’s findings reveal two faces of the FOXA1 oncogene and deepen understanding of prostate cancer evolution, while opening potential avenues for FOXA1 mutation-specific therapeutic strategies.

Additional authors: Sanjana Eyunni, Rahul Mannan, Yuping Zhang, Eleanor Young, Qiuyang Zhang, Jie Luo, Matthew Pang, Somnath Mahapatra, Jean Ching-Yi Tien, James M. George , Mustapha Jaber, Hamzah Hakkani , Sandra E. Carson, Abigail J. Todd, Noshad Hosseini, Mahnoor Gondal, Ryan J. Rebernick, Xuhong Cao, Fengyun Su, Rui Wang, Rohit Mehra, Jing Li, Marcin Cieslik

Funding/disclosures: National Cancer Institute (NCI) Specialized Programs of Research Excellence Grant P50-CA186786 (Rogel Cancer Center investigators, including AMC) National Cancer Institute Outstanding Investigator Award R35-CA231996 (AMC) Michigan Prostate SPORE Career Enhancement Program award (AP) NIH K00 Fellowship K00-CA245825 (AP) Rogel Fellowship (AP) Prostate Cancer Foundation Young Investigator Award (AP) V Scholar Award V2024-020 (AP) AMC is a Howard Hughes Medical Institute Investigator, A. Alfred Taubman Scholar, and American Cancer Society Professor

Tech transfer(s)/Conflict(s) of interest: A.M.C. is a co-founder and serves on the scientific advisory board of Lynx Dx, Flamingo Therapeutics, NuLynx Therapeutics, Medsyn Pharma, and Esanik Therapeutics. A.M.C. serves as an advisor to Tempus, Aurigene Oncology, and Ascentage. The remaining authors declare no conflicts of interests

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week

Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows


More Articles About:

Cancer Research All Research Topics Rogel Cancer Center Pathology Cancer (Oncology)
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Arul Chinnaiyan, MD, PhD

Arul Chinnaiyan, MD, PhD

Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Mother sits on a couch with a laptop on her lap while an elementary school age boy sits next to her playing on a tablet device.
Health Lab

New questionnaire aims to improve understanding of demand avoidance in children, teens

Pathological demand avoidance is a pattern of intense distress and avoidance of demands in children. A new questionnaire from University of Michigan researchers creates a structured way to assess these behaviors.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
Rachel Upjohn Building groundbreaking ceremony
News Release

How U-M helped bring depression out of the darkness

The history of the founding of the Eisenberg Family Depression Center at the University of Michigan, the nation's first center focused on research, community outreach and stigma reduction in depression and bipolar disorder.
Group of men smiling in a field
News Release

How have diagnostic and treatment decisions for prostate cancer changed in recent years?

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis by University of Michigan Rogel Cancer Center researchers, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.